Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Eur J Pharmacol ; 913: 174642, 2021 Dec 15.
Article in English | MEDLINE | ID: mdl-34822791

ABSTRACT

It is widely accepted that the stria vascularis (SV) in cochlea plays a critical role in the generation of endocochlear potential (EP) and the secretion of the endolymph. 17ß-estradiol (E2) is the most potent and abundant endogenous estrogen during the premenopausal period, thus, considered as the reference estrogen. This study aimd to investigate the protective effect of E2 by promoting the expression of vascular endothelial growth factor (VEGF) and thus promoting the vascular regeneration of the SV in elderly mice. After being treated with E2 either in vivo or in vitro, the hearing threshold changes of C57BL/6J elder mice continuously reduced, endothelial cell morphology improved, the number of endothelial cells (ECs) tubular nodes increased significantly, the ability of tubular formation enhanced significantly and the expression of VEGF increased. In vitro, cell model in conjunction with in vivo ovariectomized model was established to demonstrate for the first time that E2 promotes angiogenesis by promoting the secretion of VEGF through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway (PI3K/AKT). In conclusion, E2 demonstrated potent angiogenesis properties with significant protection against Age-Related Hearing Loss (ARHL), which provides a new idea for the improvement of ARHL.


Subject(s)
Angiogenesis Inducing Agents/pharmacology , Estradiol/pharmacology , Hearing Loss/prevention & control , Neovascularization, Physiologic/drug effects , Stria Vascularis/drug effects , Aging/physiology , Angiogenesis Inducing Agents/therapeutic use , Animals , Disease Models, Animal , Endothelial Cells/metabolism , Estradiol/therapeutic use , Female , Hearing Loss/physiopathology , Humans , Mice , Organ Culture Techniques , Regeneration/drug effects , Signal Transduction/drug effects , Stria Vascularis/physiology , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/metabolism
2.
Genes (Basel) ; 12(9)2021 08 31.
Article in English | MEDLINE | ID: mdl-34573361

ABSTRACT

The antioxidant capacity of polyphenols and flavonoids present in dietary agents aids in arresting the development of reactive oxygen species (ROS) and protecting endothelial smooth muscle cells from oxidative stress/induced necrosis. Beetroot (Beta vulgaris var. rubra L.; BVr) is a commonly consumed vegetable representing a rich source of antioxidants. Beetroot peel's bioactive compounds and their role in human umbilical vein endothelial cells (HUVECs) are still under-researched. In the present study, beetroot peel methanol extract (BPME) was prepared, and its effect on the bio-efficacy, nuclear integrity, mitochondrial membrane potential and vascular cell growth, and immunoregulation-related gene expression levels in HUVECs with induced oxidative stress were analysed. Gas chromatography-mass spectroscopy (GC-MS) results confirmed that BPME contains 5-hydroxymethylfurfural (32.6%), methyl pyruvate (15.13%), furfural (9.98%), and 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-Pyran-4-one (12.4%). BPME extract effectively enhanced cell proliferation and was confirmed by MTT assay; the nuclear integrity was confirmed by propidium iodide (PI) staining assay; the mitochondrial membrane potential (Δψm) was confirmed by JC-1 staining assay. Annexin V assay confirmed that BPME-treated HUVECs showed 99% viable cells, but only 39.8% viability was shown in HUVECs treated with H2O2 alone. In addition, BPME treatment of HUVECs for 48 h reduced mRNA expression of lipid peroxide (LPO) and increased NOS-3, Nrf-2, GSK-3ß, GPX, endothelial nitric oxide synthase (eNOS) and vascular cell growth factor (VEGF) mRNA expression levels. We found that BPME treatment decreased proinflammatory (nuclear factor-κß (F-κß), tissue necrosis factor-α (TNF-α), toll-like receptor-4 (TLR-4), interleukin-1ß (IL-1ß)) and vascular inflammation (intracellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), EDN1, IL-1ß)-related mRNA expressions. In conclusion, beetroot peel treatment effectively increased vascular smooth cell growth factors and microtubule development, whereas it decreased vascular inflammatory regulators. BPME may be beneficial for vascular smooth cell regeneration, tissue repair and anti-ageing potential.


Subject(s)
Antioxidants/pharmacology , Beta vulgaris/chemistry , Plant Extracts/pharmacology , Antioxidants/isolation & purification , Cell Proliferation/drug effects , Human Umbilical Vein Endothelial Cells , Humans , Hydrogen Peroxide/toxicity , Methanol/chemistry , Neovascularization, Physiologic/drug effects , Oxidative Stress/drug effects , Plant Extracts/isolation & purification , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/metabolism
3.
Bone ; 123: 86-91, 2019 06.
Article in English | MEDLINE | ID: mdl-30904629

ABSTRACT

Cytokines and growth factors mediate inflammatory osteolysis in response to particles released from bone implants. However, the mechanism by which this process develops is not entirely clear. Blood vessels and related factors may be required to deliver immune cells and soluble factors to the injury site. Therefore, in the current study we investigated if, vascular endothelial growth factor (VEGF), which is required for angiogenesis, mediates polymethylmethacrylate (PMMA) particles-induced osteolysis. Using bone marrow derived macrophages (BMMs) and ST2 stromal cell line, we show that PMMA particles increase VEGF expression. Further, using a murine calvarial osteolysis model, we found that PMMA injection over calvaria induce significant increase in VEGF expression as well as new vessel formation, represented by von Willebrand factor (vWF) staining. Co-treatment using a VEGF-neutralizing antibody abrogated expression of vWF, indicating decreased angiogenesis. Finally, VEGF neutralizing antibody reduced expression of Tumor necrosis factor (TNF) and decreased osteoclastogenesis induced by PMMA particles in calvariae. This work highlights the significance of angiogenesis, specifically VEGF, as key driver of PMMA particle-induced inflammatory osteolysis, inhibition of which attenuates this response.


Subject(s)
Drug Delivery Systems/methods , Osteolysis/chemically induced , Osteolysis/prevention & control , Polymethyl Methacrylate/toxicity , Skull/drug effects , Vascular Endothelial Growth Factor A/biosynthesis , Animals , Bone Cements/toxicity , Cells, Cultured , Female , Male , Mice , Mice, Inbred C57BL , Microspheres , Osteolysis/metabolism , Random Allocation , Skull/metabolism , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/antagonists & inhibitors
4.
Biochem Biophys Res Commun ; 503(4): 2653-2658, 2018 09 18.
Article in English | MEDLINE | ID: mdl-30093115

ABSTRACT

Mesenchymal stromal cell (MSC) derived exosomes mediate tissue protection and regeneration in many injuries and diseases by modulating cell protein production, protecting from apoptosis, inhibiting inflammation, and increasing angiogenesis. In the present study, daily intraperitoneal injection of MSC-derived exosomes protected alveolarization and angiogenesis in a newborn rat model of bronchopulmonary dysplasia (BPD) induced by 14 days of neonatal hyperoxia exposure (85% O2). Exosome treatment during hyperoxia prevented disruption of alveolar growth, increased small blood vessel number, and inhibited right heart hypertrophy at P14, P21, and P56. In vitro, exosomes significantly increased tube-like network formation by HUVEC, in part through a VEGF mediated mechanism. In summary, daily intraperitoneal injection of exosomes increased blood vessel number and size in the lung through pro-angiogenic mechanisms. MSC-derived exosomes therefore have both anti-inflammatory and pro-angiogenic mechanism to protect the lung from hyperoxia induced lung and heart disease associated with BPD.


Subject(s)
Bronchopulmonary Dysplasia/prevention & control , Cardiomegaly/prevention & control , Exosomes/physiology , Hyperoxia/prevention & control , Mesenchymal Stem Cells/chemistry , Vascular Endothelial Growth Factor A/genetics , Animals , Animals, Newborn , Bone Marrow Cells/chemistry , Bone Marrow Cells/cytology , Bronchopulmonary Dysplasia/genetics , Bronchopulmonary Dysplasia/metabolism , Bronchopulmonary Dysplasia/pathology , Cardiomegaly/genetics , Cardiomegaly/metabolism , Cardiomegaly/pathology , Disease Models, Animal , Exosomes/transplantation , Female , Gene Expression Regulation , Hyperoxia/genetics , Hyperoxia/metabolism , Hyperoxia/pathology , Injections, Intraperitoneal , Lung/blood supply , Lung/metabolism , Lung/pathology , Mesenchymal Stem Cells/cytology , Neovascularization, Physiologic/genetics , Oxygen/toxicity , Pregnancy , Primary Cell Culture , Rats , Rats, Sprague-Dawley , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/metabolism
5.
J Ethnopharmacol ; 219: 152-160, 2018 Jun 12.
Article in English | MEDLINE | ID: mdl-29126989

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Rubia cordifolia is a common traditional Chinese medicine that promotes blood circulation and eliminates blood stasis, and has been used to cure diseases related to blood stasis syndrome (BSS) clinically for many years. It has been previously demonstrated that anti-thrombosis and pro-angiogenesis can improve BSS. However, the anti-thrombotic and pro-angiogenic activities of Rubia cordifolia have not been well investigated. AIM OF STUDY: To determine the potential anti-thrombotic and pro-angiogenic activities of Rubia cordifolia and to elucidate the underlying mechanisms. In addition, the major chemical constituents of Rubia cordifolia extract (QC) were qualitatively analysed by UPLC-Q-TOF/MS to explore the association between pharmacological activity and chemical constituents. MATERIAL AND METHODS: The QC samples were composed of a 95% ethanol extract and an aqueous extract following extraction using 95% ethanol. UPLC-Q-TOF/MS was used to analyse the major chemical constituents of QC. For the anti-thrombotic experiment of QC, a phenylhydrazine (PHZ)-induced AB strain zebrafish thrombosis model was used. The zebrafish larvae were stained using O-dianisidine, and the heart and caudal vein of the zebrafish were observed and imaged with a fluorescence microscope. The staining intensity of erythrocytes in the heart (SI) of each group and the morphology of thrombus in the caudal vein were used to assess the anti-thrombotic effect of QC. For the pro-angiogenic assay of QC, the intersegmental blood vessel (ISV) insufficiency model of Tg(fli-1: EGFP)y1 transgenic zebrafish (Flik zebrafish), which was induced by the VEGF receptor tyrosine kinase inhibitor II (VRI), was used. The morphology of the intact ISVs and defective ISVs was observed to evaluate the pro-angiogenic activity of QC. The mechanism involved in promoting angiogenesis was studied with real-time PCR. RESULTS: A total of 12 components in QC were identified based on standard compounds and references, including nine anthraquinones and three naphthoquinones. After treatment with QC, the PHZ-induced thrombosis in AB strain zebrafish larvae decreased to a certain degree, which we believe was related to its dosages, and the therapeutic effect within the 50-200 µg/mL QC treatment groups was especially prominent (P < 0.01, P < 0.001) compared to that in the PHZ model group. Similarly, QC also recovered the loss of the ISVs, which was induced by VRI in Flik zebrafish larvae, which have a certain dose-effect relationship. The pro-angiogenic activity of QC was also conspicuous (P < 0.01, P < 0.001) compared to that of the VRI model group. The following real-time PCR assay proved that QC significantly restored the VRI-induced downregulation of vWF, VEGF-A, kdrl, and flt-1 in Flik zebrafish (P < 0.05, P < 0.01, P < 0.001). CONCLUSIONS: A total of 12 compounds from QC were analysed by UPLC-Q-TOF/MS. The data of the pharmacological experiments demonstrated that QC presented anti-thrombotic and pro-angiogenic activities in zebrafish, and the principal active components were likely anthraquinones and naphthoquinones. Thus, the current study provided a theoretical basis for the clinical use of Rubia cordifolia as a traditional Chinese medicine in promoting blood circulation and eliminating stasis.


Subject(s)
Angiogenesis Inducing Agents/pharmacology , Drugs, Chinese Herbal/pharmacology , Fibrinolytic Agents/pharmacology , Rubia , Angiogenesis Inducing Agents/isolation & purification , Angiogenesis Inducing Agents/therapeutic use , Animals , Animals, Genetically Modified , Disease Models, Animal , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/therapeutic use , Fibrinolytic Agents/isolation & purification , Fibrinolytic Agents/therapeutic use , Thrombosis/diagnostic imaging , Thrombosis/drug therapy , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/biosynthesis , Zebrafish
6.
J Biol Chem ; 292(31): 12787-12800, 2017 08 04.
Article in English | MEDLINE | ID: mdl-28637870

ABSTRACT

Stress-induced p38 mitogen-activated protein kinase (MAPK) activity is implicated in pathological remodeling in the heart. For example, constitutive p38 MAPK activation in cardiomyocytes induces pathological features, including myocyte hypertrophy, apoptosis, contractile dysfunction, and fetal gene expression. However, the physiological function of cardiomyocyte p38 MAPK activity in beneficial compensatory vascular remodeling is unclear. This report investigated the functional role and the underlying mechanisms of cardiomyocyte p38 MAPK activity in cardiac remodeling induced by chronic stress. Using both in vitro and in vivo model systems, we found that p38 MAPK activity is required for hypoxia-induced pro-angiogenic activity from cardiomyocytes and that p38 MAPK activation in cardiomyocyte is sufficient to promote paracrine signaling-mediated, pro-angiogenic activity. We further demonstrate that VEGF is a paracrine factor responsible for the p38 MAPK-mediated pro-angiogenic activity from cardiomyocytes and that p38 MAPK pathway activation is sufficient for inducing VEGF secretion from cardiomyocytes in an Sp1-dependent manner. More significantly, cardiomyocyte-specific inactivation of p38α in mouse heart impaired compensatory angiogenesis after pressure overload and promoted early onset of heart failure. In summary, p38αMAPK has a critical role in the cross-talk between cardiomyocytes and vasculature by regulating stress-induced VEGF expression and secretion in cardiomyocytes. We conclude that as part of a stress-induced signaling pathway, p38 MAPK activity significantly contributes to both pathological and compensatory remodeling in the heart.


Subject(s)
Endothelium, Vascular/metabolism , Mitogen-Activated Protein Kinase 14/metabolism , Myocardial Ischemia/metabolism , Myocardial Revascularization , Myocytes, Cardiac/metabolism , Animals , Animals, Newborn , Cell Hypoxia , Cells, Cultured , Crosses, Genetic , Endothelium, Vascular/cytology , Endothelium, Vascular/pathology , Enzyme Activation , Gene Expression Regulation , Human Umbilical Vein Endothelial Cells/cytology , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Male , Mice, Knockout , Mice, Transgenic , Mitogen-Activated Protein Kinase 14/chemistry , Mitogen-Activated Protein Kinase 14/genetics , Myocardial Ischemia/pathology , Myocytes, Cardiac/cytology , Myocytes, Cardiac/pathology , RNA Interference , Rats, Sprague-Dawley , Recombinant Proteins/metabolism , Sp1 Transcription Factor/antagonists & inhibitors , Sp1 Transcription Factor/genetics , Sp1 Transcription Factor/metabolism , Sus scrofa , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/agonists , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/metabolism
7.
Nat Rev Dis Primers ; 3: 17009, 2017 Mar 09.
Article in English | MEDLINE | ID: mdl-28276433

ABSTRACT

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic VHL mutations have been described for some time, more-recent cancer genomic studies have identified mutations in epigenetic regulatory genes and demonstrated marked intra-tumour heterogeneity, which could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed with surgery, whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such as cabozantinib and lenvatinib; immunotherapies, such as nivolumab, have also been added to the armamentarium for metastatic RCC. Here, we provide an overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy.


Subject(s)
Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/diagnosis , Axitinib , Bevacizumab/therapeutic use , Carcinoma, Renal Cell/physiopathology , Humans , Imidazoles/therapeutic use , Indazoles/therapeutic use , Indoles/therapeutic use , Kidney/anatomy & histology , Kidney Diseases/complications , Kidney Diseases/diagnosis , Kidney Diseases/drug therapy , Niacinamide/analogs & derivatives , Niacinamide/therapeutic use , Phenylurea Compounds/therapeutic use , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Quality of Life/psychology , Risk Factors , Sorafenib , Sulfonamides/therapeutic use , Sunitinib , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/therapeutic use
8.
J Diabetes Complications ; 31(4): 653-663, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28131600

ABSTRACT

AIM: The aims of this study are to investigate the relative regulation between miR-126 and VEGF/PI3K/AKT signaling pathway in retinal vascular endothelial cells. METHODS: Rhesus macaque choroid-retinal endothelial cell line (RF/6A) cells were cultured in high glucose to imitate the conditions occurring in DR. First, we detected the expression of miR-126, VEGFA and PIK3R2 in RF/6A cells on the condition of high glucose by q-PCR and western blot. Then, after addition of miR-126 mimics and miR-126 inhibitor, we investigated the function of miR-126 in RF/6A cells by scratch wound, Transwell migration and tube formation assays, and the effect of miR-126 on the expression of VEGFA, PIK3R2 and AKT. Moreover, bioinformatics analysis and luciferase array were used to confirm the direct or specific regulation of miR-126 to VEGFA or PIK3R2. RESULTS: Here, first, we found that high glucose could induce the decrease of miR-126 and the increase of VEGFA and PIK3R2 in RF/6A. Then, by scratch wound, Transwell migration and tube formation assays, we found that miR-126 overexpression could inhibit the migration and sprouting of RF/6A cells induced by high glucose, while knockdown of miR-126 led to the opposite results. Moreover, overexpression of miR-126 inhibited the increased expression of VEGFA, PIK3R2, SDF-1α, VCAM-1, and SPRED1, and the activation of AKT1 induced by high glucose and miR-126 inhibitor caused the opposite results which were determined by q-PCR and western blot. In addition, by luciferase assay, we found that miR-126 could directly negatively regulate VEGFA and PIK3R2. CONCLUSION: Our results suggest that miR-126 overexpression inhibits the migration and sprouting of RF/6A cells induced by high glucose which might possibly be by blocking VEGFA and PIK3R2 in the VEGF/PI3K/AKT signaling pathway.


Subject(s)
Choroid/metabolism , Eye Proteins/antagonists & inhibitors , Glucose/metabolism , MicroRNAs/metabolism , Phosphoinositide-3 Kinase Inhibitors , Retina/metabolism , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Animals , Cell Line , Cell Movement , Choroid/pathology , Class Ia Phosphatidylinositol 3-Kinase/chemistry , Class Ia Phosphatidylinositol 3-Kinase/genetics , Class Ia Phosphatidylinositol 3-Kinase/metabolism , Computational Biology , Diabetic Retinopathy/metabolism , Diabetic Retinopathy/pathology , Eye Proteins/agonists , Eye Proteins/genetics , Eye Proteins/metabolism , Gene Expression Regulation , Gene Knockdown Techniques , Genes, Reporter , Hyperglycemia/metabolism , Hyperglycemia/pathology , Macaca mulatta , MicroRNAs/antagonists & inhibitors , MicroRNAs/chemistry , Molecular Mimicry , Osmolar Concentration , RNA/metabolism , Retina/pathology , Signal Transduction , Stereoisomerism , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
9.
Nutr Neurosci ; 20(6): 336-342, 2017 Jul.
Article in English | MEDLINE | ID: mdl-26788968

ABSTRACT

Recent evidence indicates that hypoxia-inducible vascular endothelial growth factor (VEGF) has neurotrophic and neuroprotective effects on neuronal and glial cells. On the other hand, recent epidemiological studies showed that daily coffee consumption has been associated with a lower risk of several neuronal disorders. Therefore, we investigated the effect of coffee on VEGF expression in human neuroblastoma SH-SY5Y cells. We found that even low concentration of coffee (<2%) strongly induced VEGF expression via an activation of HIF-1α. The activation of HIF-1α by coffee was attributed to the coffee-dependent inhibition of prolyl hydroxylation of HIF1α, which is essential for proteolytic degradation of HIF-1α. However, no inhibition was observed at the catalytic activity in vitro. Coffee component(s) responsible for the activation of HIF-1α was not major constituents such as caffeine, caffeic acid, chlorogenic acid, and trigonelline, but was found to emerge during roasting process. The active component(s) was extractable with ethyl acetate. Our results suggest that daily consumption of coffee may induce VEGF expression in neuronal cells. This might be related to protective effect of coffee on neural disorders such as Alzheimer's disease and Parkinson's disease.


Subject(s)
Coffee/metabolism , Gene Expression Regulation , Hypoxia-Inducible Factor 1, alpha Subunit/agonists , Neurons/metabolism , Neuroprotective Agents/metabolism , Plant Extracts/metabolism , Vascular Endothelial Growth Factor A/agonists , Acetates/chemistry , Cell Line, Tumor , Coffee/chemistry , Food Handling , Functional Food , Gene Expression Regulation, Neoplastic , Hot Temperature , Humans , Hydroxylation , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Neoplasm Proteins/agonists , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neuroblastoma/metabolism , Neuroprotection , Neuroprotective Agents/isolation & purification , Plant Extracts/isolation & purification , Proline/metabolism , Protein Processing, Post-Translational , Solvents/chemistry , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
10.
J Tissue Eng Regen Med ; 11(11): 3241-3252, 2017 11.
Article in English | MEDLINE | ID: mdl-27943613

ABSTRACT

Here we investigated the impact of hypoxic environment on the angiogenic properties of early-outgrowth endothelial progenitor cells (EPCs), with particular focus on the role of secreted vascular endothelial growth factor-A (VEGF-A) and stromal derived factor-1 (SDF-1) in mediating these effects. We found that cultured EPCs secreted factors with paracrine effects on chemotaxis, migration, proliferation and tube formation of mature endothelial cells (ECs), and these properties were not affected by hypoxia. Depletion of VEGF-A did not change the ability of EPC-conditioned medium (CM) to promote EC migration and tube formation in vitro, suggesting that the pro-angiogenic paracrine effects of EPCs did not totally rely on the presence of VEGF-A. These findings were confirmed by in vivo experiments, on a mouse model of hind limb ischaemia, which showed that VEGF-depleted EPC-CM sustained tissue perfusion at the same level as complete EPC-CM. However, concomitant deletion of VEGF-A and SDF-1 in EPC-CM impaired the pro-angiogenic properties of EPC-CM, by inhibition of EC spreading in culture, tube-like structure formation on Matrigel support, in vivo neovessels formation and ischaemic hind limb regeneration. Taken together, our data demonstrate that: (i) hypoxia does not affect the capacity of EPCs to support the angiogenic process; (ii) the absence of either VEGF-A or SDF-1 from EPC-CM can be rescued by the presence of the other one, so that the overall angiogenic effects remain unchanged; and (iii) and the concomitant deletion of VEGF-A and SDF-1 from EPC-CM impairs its pro-angiogenic effect, both in vitro and in vivo. Copyright © 2016 John Wiley & Sons, Ltd.


Subject(s)
Chemokine CXCL12 , Endothelial Progenitor Cells/metabolism , Neovascularization, Physiologic , Vascular Endothelial Growth Factor A , Animals , Chemokine CXCL12/agonists , Chemokine CXCL12/metabolism , Hindlimb/blood supply , Hindlimb/metabolism , Humans , Ischemia/metabolism , Ischemia/therapy , Mice , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/metabolism
11.
Sci Rep ; 6: 20643, 2016 Feb 11.
Article in English | MEDLINE | ID: mdl-26865366

ABSTRACT

Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF intrinsically in the tendon, we effectively corrected the insufficiency of the tendon healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p < 0.05 or p < 0.01), (2) significantly promoted production of type I collagen and other extracellular molecules (p < 0.01) and accelerated cellular proliferation, and (3) significantly increased tendon strength by 68-91% from week 2 after AAV2-bFGF treatment and by 82-210% from week 3 after AAV2-VEGF compared with that of the controls (p < 0.05 or p < 0.01). Moreover, the transgene expression dissipated after healing was complete. These findings show that the gene transfers provide an optimistic solution to the insufficiencies of the intrinsic healing capacity of the tendon and offers an effective therapeutic possibility for patients with tendon disunion.


Subject(s)
Dependovirus/genetics , Fibroblast Growth Factor 2/genetics , Tendon Injuries/therapy , Vascular Endothelial Growth Factor A/genetics , Wound Healing/genetics , Animals , Cell Proliferation , Chickens , Collagen Type I/agonists , Collagen Type I/genetics , Collagen Type I/metabolism , Dependovirus/metabolism , Fibroblast Growth Factor 2/agonists , Fibroblast Growth Factor 2/metabolism , Fibronectins/agonists , Fibronectins/genetics , Fibronectins/metabolism , Gene Expression Regulation , Genetic Therapy/methods , Genetic Vectors/chemistry , Genetic Vectors/metabolism , Laminin/agonists , Laminin/genetics , Laminin/metabolism , Primary Cell Culture , Tendon Injuries/genetics , Tendon Injuries/metabolism , Tendon Injuries/pathology , Tendons/metabolism , Tendons/pathology , Tenocytes/cytology , Tenocytes/metabolism , Tensile Strength , Transgenes , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/metabolism
12.
Acta Biomater ; 29: 239-247, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26485166

ABSTRACT

Growth factors (GFs) are potent signaling molecules that act in a coordinated manner in physiological processes such as tissue healing or angiogenesis. Co-immobilizing GFs on materials while preserving their bioactivity still represents a major challenge in the field of tissue regeneration and bioactive implants. In this study, we explore the potential of an oriented immobilization technique based on two high affinity peptides, namely the Ecoil and Kcoil, to allow for the simultaneous capture of the epidermal growth factor (EGF) and the vascular endothelial growth factor (VEGF) on a chondroitin sulfate coating. This glycosaminoglycan layer was selected as it promotes cell adhesion but reduces non-specific adsorption of plasma proteins. We demonstrate here that both Ecoil-tagged GFs can be successfully immobilized on chondroitin sulfate surfaces that had been pre-decorated with the Kcoil peptide. As shown by direct ELISA, changing the incubation concentration of the various GFs enabled to control their grafted amount. Moreover, cell survival studies with endothelial and smooth muscle cells confirmed that our oriented tethering strategy preserved GF bioactivity. Of salient interest, co-immobilizing EGF and VEGF led to better cell survival compared to each GF captured alone, suggesting a synergistic effect of these GFs. Altogether, these results demonstrate the potential of coiled-coil oriented GF tethering for the co-immobilization of macromolecules; it thus open the way to the generation of biomaterials surfaces with fine-tuned biological properties. STATEMENT OF SIGNIFICANCE: Growth factors are potent signaling molecules that act in a coordinated manner in physiological processes such as tissue healing or angiogenesis. Controlled coimmobilization of growth factors on biomaterials while preserving their bioactivity represents a major challenge in the field of tissue regeneration and bioactive implants. This study demonstrates the potential of an oriented immobilization technique based on two high affinity peptides to allow for the simultaneous capture of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF). Our system allowed an efficient control on growth factor immobilization by adjusting the incubation concentrations of EGF and VEGF. Of salient interest, co-immobilizing of specific ratios of EGF and VEGF demonstrated a synergistic effect on cell survival compared to each GF captured alone.


Subject(s)
Epidermal Growth Factor/pharmacology , Human Umbilical Vein Endothelial Cells/metabolism , Immobilized Proteins/pharmacology , Vascular Endothelial Growth Factor A/pharmacology , Cell Survival/drug effects , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacology , Drug Synergism , Epidermal Growth Factor/agonists , Epidermal Growth Factor/chemistry , Human Umbilical Vein Endothelial Cells/cytology , Humans , Immobilized Proteins/agonists , Immobilized Proteins/chemistry , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/chemistry
13.
Toxicon ; 110: 1-11, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26615089

ABSTRACT

Alternagin-C (ALT-C) is a disintegrin-like protein purified from the venom of the snake, Rhinocerophis alternatus. Recent studies showed that ALT-C is able to induce vascular endothelial growth factor (VEGF) expression, endothelial cell proliferation and migration, angiogenesis and to increase myoblast viability. This peptide, therefore, can play a crucial role in tissue regeneration mechanisms. The aim of this study was to evaluate the effects of a single dose of alternagin-C (0.5 mg kg(-1), via intra-arterial) on in vitro cardiac function of the freshwater fish traíra, Hoplias malabaricus, after 7 days. ALT-C treatment increased the cardiac performance promoting: 1) significant increases in the contraction force and in the rates of contraction and relaxation with concomitant decreases in the values of time to the peak tension and time to half- and 90% relaxation; 2) improvement in the cardiac pumping capacity and maximal electrical stimulation frequency, shifting the optimum frequency curve upward and to the right; 3) increases in myocardial VEGF levels and expression of key Ca(2+)-cycling proteins such as SERCA (sarcoplasmic reticulum Ca(2+)-ATPase), PLB (phospholamban), and NCX (Na(+)/Ca(2+) exchanger); 4) abolishment of the typical negative force-frequency relationship of fish myocardium. In conclusion, this study indicates that ALT-C improves cardiac function, by increasing Ca(2+) handling efficiency leading to a positive inotropism and chronotropism. The results suggest that ALT-C may lead to better cardiac output regulation indicating its potential application in therapies for cardiac contractile dysfunction.


Subject(s)
Bothrops , Cardiotonic Agents/pharmacology , Disintegrins/pharmacology , Heart Rate/drug effects , Heart Ventricles/drug effects , Myocardial Contraction/drug effects , Reptilian Proteins/pharmacology , Animals , Aquaculture , Calcium-Binding Proteins/agonists , Calcium-Binding Proteins/genetics , Calcium-Binding Proteins/metabolism , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/isolation & purification , Characiformes , Crotalid Venoms/chemistry , Disintegrins/administration & dosage , Disintegrins/isolation & purification , Fish Proteins/agonists , Fish Proteins/genetics , Fish Proteins/metabolism , Gene Expression Regulation/drug effects , Heart Ventricles/enzymology , Heart Ventricles/metabolism , Injections, Intra-Arterial , Random Allocation , Reptilian Proteins/administration & dosage , Reptilian Proteins/isolation & purification , Sarcoplasmic Reticulum Calcium-Transporting ATPases/chemistry , Sarcoplasmic Reticulum Calcium-Transporting ATPases/genetics , Sarcoplasmic Reticulum Calcium-Transporting ATPases/metabolism , Sodium-Calcium Exchanger/agonists , Sodium-Calcium Exchanger/genetics , Sodium-Calcium Exchanger/metabolism , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Ventricular Function/drug effects
14.
Clin Exp Immunol ; 184(1): 62-72, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26671547

ABSTRACT

High-mobility group box 1 (HMGB1) has been implicated in angiogenesis and rheumatoid arthritis (RA). The aim of this study was to define more clearly the role of HMGB1 in the synovial angiogenesis and pathogenesis of an immune model of arthritis. BALB/c mice were injected with monoclonal anti-collagen antibody cocktail followed by lipopolysaccharide to induce arthritis. HMGB1 and vascular endothelial growth factor (VEGF) were over-expressed in the areas of the synovium where more inflammation and neoangiogenesis were present. The selective blockade of HMGB1 or VEGF resulted alternatively in a lower severity of arthritis evaluated by the arthritis index. Furthermore, exogenous HMGB1 administration caused a worsening of arthritis, associated with VEGF up-regulation and increased synovial angiogenesis. The selective inhibition of VEGF also resulted in no induction of arthritis in mice receiving exogenous HMGB1. Cytokine enzyme-linked immunosorbent assay (ELISA) analyses performed on peripheral blood and synovial fluid demonstrated a significant reduction of interleukin (IL)-1ß, IL-6 and tumour necrosis factor (TNF)-α in mice where HMGB1 and VEGF pathways were blocked. Interestingly, the selective blockade of HMGB1 and VEGF resulted in an increase of the peripheral IL-17A concentration. The development of arthritis mediated by HMGB1 and the synovial angiogenesis can be blocked by inhibiting the VEGF activity. The proinflammatory and proangiogenic cytokine IL-17A was increased when HMGB1 is inhibited, but the synovial angiogenesis was nevertheless reduced in this model of arthritis. Taken together, these findings shed new light on the role of this nuclear protein in the pathogenesis of arthritis in an RA-like model.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antibodies/blood , Arthritis, Experimental/drug therapy , HMGB1 Protein/immunology , Peptides/pharmacology , Vascular Endothelial Growth Factor A/immunology , Vascular Endothelial Growth Factor Receptor-1/pharmacology , Animals , Arthritis, Experimental/genetics , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Collagen Type II/blood , Collagen Type II/immunology , Gene Expression , HMGB1 Protein/antagonists & inhibitors , HMGB1 Protein/genetics , HMGB1 Protein/pharmacology , Interleukin-17/genetics , Interleukin-17/immunology , Interleukin-1beta/genetics , Interleukin-1beta/immunology , Interleukin-6/genetics , Interleukin-6/immunology , Male , Mice , Mice, Inbred BALB C , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/immunology , Neovascularization, Pathologic/pathology , Neovascularization, Pathologic/prevention & control , Severity of Illness Index , Synovial Membrane/drug effects , Synovial Membrane/immunology , Synovial Membrane/pathology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/genetics
15.
Pharm Biol ; 54(3): 419-32, 2016.
Article in English | MEDLINE | ID: mdl-25894211

ABSTRACT

CONTEXT: Wound healing is a consequence of a complex process involving inflammatory, proliferative, and remodeling phases. Naringin, a flavanone glycoside, is associated with modulation of various oxido-inflammatory and growth factors. AIM: The aim of this study is to evaluate the wound-healing activity of naringin ointment formulation (NOF) on experimental wound models. MATERIALS AND METHODS: A soft paraffin-based cream containing 1, 2, and 4% (w/w) naringin was formulated and evaluated for physicochemical characters. Excision wounds and incisions wounds were used to study the topical effect of NOF for 20 d (once a day) on various biochemical, molecular, and histological parameters. RESULTS: NOF (2 and 4%, w/w) treatment showed a significant decrease (p < 0.05) in wound area and epithelization period whereas the rate of wound contraction increased significantly (p < 0.05). The altered levels of oxido-nitrosative stress (SOD, GSH, MDA, MPO, and NO) were significantly (p < 0.05) restored by NOF. Treatment produced a significant increase (p < 0.05) in tensile strength, hydroxyproline content, and protein content. TNF-α, IL-1ß, IL-6, IL-8, NF-κB, smad-7, and Bax mRNA expression were significantly down-regulated (p < 0.05) by NOF, whereas polymerase gamma (pol-γ), smad-3, VEGF and TGF-ß, and collagen-1 mRNA expressions were significantly up-regulated (p < 0.05) by NOF. Histological alterations in wound skin were also restored by NOF. CONCLUSION: NOF exerts wound healing potential via down-regulated expression of inflammatory (NF-κB, TNF-α, and ILs), apoptotic (pol-γ and Bax), and up-regulated growth factor (VEGF and TGF-ß) expression, thus modulating collagen-1 expression to induce angiogenesis leading to wound healing.


Subject(s)
Apoptosis/drug effects , Flavanones/administration & dosage , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Vascular Endothelial Growth Factor A/biosynthesis , Wound Healing/drug effects , Administration, Topical , Animals , Apoptosis/physiology , Chemistry, Pharmaceutical , Lymphotoxin-alpha/agonists , Lymphotoxin-alpha/biosynthesis , Male , Ointments , Rats , Rats, Wistar , Vascular Endothelial Growth Factor A/agonists , Wound Healing/physiology
16.
Klin Khir ; (5): 41-3, 2015 May.
Article in Russian | MEDLINE | ID: mdl-26419033

ABSTRACT

The results of examination of patients, suffering chronic ischemia of the lower extremities (LE) stages IIB - III (according to Fontaine), in whom preparation Neovasculgen was used in complex of medicinal therapy, were presented. In terms of follow-up before 12 months the distance, which the patients passed before the pain occurrence, have enhanced by 92.2%, and the ankle-brachial index--by 30.9%. Complications while application of the preparation were absent. Due to the treatment conducted there were LE saved and the patients' quality of life improved.


Subject(s)
Angiogenesis Inducing Agents/therapeutic use , Atherosclerosis/drug therapy , Ischemia/drug therapy , Vascular Endothelial Growth Factor A/agonists , Ankle Brachial Index , Atherosclerosis/metabolism , Atherosclerosis/physiopathology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiopathology , Female , Gene Expression/drug effects , Humans , Injections, Intramuscular , Ischemia/metabolism , Ischemia/physiopathology , Lower Extremity/blood supply , Lower Extremity/physiopathology , Male , Middle Aged , Neovascularization, Physiologic/drug effects , Pain/prevention & control , Quality of Life , Treatment Outcome , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Walking
17.
Antimicrob Agents Chemother ; 59(12): 7205-13, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26324277

ABSTRACT

Periostitis, which is characterized by bony pain and diffuse periosteal ossification, has been increasingly reported with prolonged clinical use of voriconazole. While resolution of clinical symptoms following discontinuation of therapy suggests a causative role for voriconazole, the biological mechanisms contributing to voriconazole-induced periostitis are unknown. To elucidate potential mechanisms, we exposed human osteoblasts in vitro to voriconazole or fluconazole at 15 or 200 µg/ml (reflecting systemic or local administration, respectively), under nonosteogenic or osteogenic conditions, for 1, 3, or 7 days and evaluated the effects on cell proliferation (reflected by total cellular DNA) and osteogenic differentiation (reflected by alkaline phosphatase activity, calcium accumulation, and expression of genes involved in osteogenic differentiation). Release of free fluoride, vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) was also measured in cell supernatants of osteoblasts exposed to triazoles, with an ion-selective electrode (for free fluoride) and enzyme-linked immunosorbent assays (ELISAs) (for VEGF and PDGF). Voriconazole but not fluconazole significantly enhanced the proliferation and differentiation of osteoblasts. In contrast to clinical observations, no increases in free fluoride levels were detected following exposure to either voriconazole or fluconazole; however, significant increases in the expression of VEGF and PDGF by osteoblasts were observed following exposure to voriconazole. Our results demonstrate that voriconazole can induce osteoblast proliferation and enhance osteogenic activity in vitro. Importantly, and in contrast to the previously proposed mechanism of fluoride-stimulated osteogenesis, our findings suggest that voriconazole-induced periostitis may also occur through fluoride-independent mechanisms that enhance the expression of cytokines that can augment osteoblastic activity.


Subject(s)
Antifungal Agents/pharmacology , Fluconazole/pharmacology , Osteoblasts/drug effects , Osteogenesis/drug effects , Voriconazole/pharmacology , Alkaline Phosphatase/genetics , Alkaline Phosphatase/metabolism , Calcium/metabolism , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Gene Expression/drug effects , Humans , Osteoblasts/cytology , Osteoblasts/metabolism , Osteogenesis/genetics , Platelet-Derived Growth Factor/agonists , Platelet-Derived Growth Factor/genetics , Platelet-Derived Growth Factor/metabolism , Primary Cell Culture , Signal Transduction , Sodium Fluoride/pharmacology , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
18.
Molecules ; 20(7): 12512-24, 2015 Jul 09.
Article in English | MEDLINE | ID: mdl-26184137

ABSTRACT

The aim of this study was to investigate novel chalcones with potent angiogenic activities in vivo. Chalcone-based derivatives were evaluated using a transgenic zebrafish line with fluorescent vessels to real-time monitor the effect on angiogenesis. Results showed that the chalcone analogues did not possess anti-angiogenic effect on zebrafish vasculatures; instead, some of them displayed potent pro-angiogenic effects on the formation of the sub-intestinal vein. Similar pro-angiogenic effects can also be seen on wild type zebrafish embryos. Moreover, the expression of vegfa, the major regulator for angiogenesis, was also upregulated in their treatment. Taken together, we have synthesized and identified a series of novel chalcone-based derivatives as potent in vivo pro-angiogenic compounds. These novel compounds hold potential for therapeutic angiogenesis.


Subject(s)
Angiogenesis Inducing Agents/pharmacology , Chalcones/pharmacology , Gene Expression Regulation, Developmental , Neovascularization, Physiologic/drug effects , Vascular Endothelial Growth Factor A/agonists , Zebrafish Proteins/agonists , Angiogenesis Inducing Agents/chemical synthesis , Animals , Animals, Genetically Modified , Chalcones/chemical synthesis , Embryo, Nonmammalian , Genes, Reporter , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Molecular Structure , Morphogenesis/drug effects , Structure-Activity Relationship , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Zebrafish , Zebrafish Proteins/genetics , Zebrafish Proteins/metabolism
19.
Genet Mol Res ; 14(4): 19203-10, 2015 Dec 29.
Article in English | MEDLINE | ID: mdl-26782573

ABSTRACT

Extracorporeal cardiac shock wave (SW) therapy is an effective, safe, and non-invasive therapeutic strategy for severe coronary artery disease. Shock wave therapy might affect cardiac tissues because of its ability to promote angiogenesis. In this report, we investigated if the up-regulation of vascular endothelial growth factor (VEGF) by SW therapy is involved in cell proliferation in cultured endothelial cells. After human umbilical vein endothelial cells were treated with SW, the expression and secretion of VEGF as well as cell proliferation were analyzed. We also determined the mechanism underlying SW-induced the extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) using western blotting. Our results demonstrated that SW treatment induced VEGF expression in endothelial cells in a hypoxia-inducible factor 1-independent manner. Up-regulation of VEGF expression led to an increase in its concentration in the cultured medium. The autocrine VEGF in the medium activated the ERK MAPK signaling, which in turn enhanced cell proliferation. Therefore, we concluded that VEGF mediates SW application-induced endothelial cell proliferation in a cell-autonomous manner.


Subject(s)
Autocrine Communication/radiation effects , Cell Proliferation/radiation effects , Human Umbilical Vein Endothelial Cells/radiation effects , Vascular Endothelial Growth Factor A/genetics , Autocrine Communication/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Cell Survival/radiation effects , Flavonoids/pharmacology , Gene Expression Regulation , High-Energy Shock Waves/therapeutic use , Human Umbilical Vein Endothelial Cells/drug effects , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Mitogen-Activated Protein Kinase 3/genetics , Mitogen-Activated Protein Kinase 3/metabolism , Protein Kinase Inhibitors/pharmacology , Quinazolines/pharmacology , Signal Transduction , Ultrasonic Therapy , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/metabolism
20.
J Diabetes Complications ; 28(4): 436-47, 2014.
Article in English | MEDLINE | ID: mdl-24731763

ABSTRACT

Diabetic foot ulcer is closely associated with peripheral vascular disease. Enhancement of tissue oxidative stress, reduction of nitric oxide (NO) and angiogenic growth factors, and abnormal matrix metalloproteinase (MMP) activity are pathophysiological factors in post-ischemic neovascularization and diabetic wound healing. Our previous study demonstrated that the Chinese 2-herb formula, NF3, showed significant wound healing effects on diabetic foot ulcer rats. A novel rat diabetic foot ulcer with hindlimb ischemia model was established in order to strengthen our claims on the diabetic wound healing and post-ischemic neovascularization effects of NF3. Our results demonstrate that NF3 can significantly reduce the wound area of the diabetic foot ulcer rat with hindlimb ischemia by 21.6% (p<0.05) compared with the control group. In addition, flow cytometric analysis revealed that NF3 could boost circulating EPC levels for local wound vessel incorporation. Immunohistochemical analysis showed that NF3 could significantly augment blood vessel density, VEGF and eNOS expression, and attenuate tissue oxidative stress of ischemic muscles (p<0.001). NF3 significantly stimulated MMP activity involved in angiogenesis. Our study shows, for the first time, the beneficial effects of NF3 in wound healing and post-ischemic neovascularization in diabetes.


Subject(s)
Angiogenesis Inducing Agents/therapeutic use , Diabetic Foot/drug therapy , Disease Models, Animal , Drugs, Chinese Herbal/therapeutic use , Neovascularization, Physiologic/drug effects , Up-Regulation/drug effects , Wound Healing/drug effects , Animals , Biomarkers/blood , Biomarkers/metabolism , Diabetic Foot/etiology , Diabetic Foot/metabolism , Diabetic Foot/pathology , Endothelial Progenitor Cells/drug effects , Endothelial Progenitor Cells/metabolism , Endothelial Progenitor Cells/pathology , Female , Hindlimb , Ischemia/physiopathology , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Muscle, Skeletal/blood supply , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Nitric Oxide Synthase Type III/chemistry , Nitric Oxide Synthase Type III/metabolism , Oxidative Stress/drug effects , Rats, Wistar , Vascular Endothelial Growth Factor A/agonists , Vascular Endothelial Growth Factor A/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...